Tempest Therapeutics (NASDAQ:TPST) Trading Down 3.9% – Here’s Why

Tempest Therapeutics, Inc. (NASDAQ:TPST)’s share price dropped 3.9% during mid-day trading on Wednesday . The company traded as low as $0.9489 and last traded at $0.9511. 83,599 shares were traded during mid-day trading, a decline of 51% from the average daily volume of 170,982 shares. The stock had previously closed at $0.9902.

Wall Street Analysts Forecast Growth

A number of research firms have commented on TPST. Zacks Research cut Tempest Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tempest Therapeutics in a research note on Monday, July 13th. Finally, Wall Street Zen cut Tempest Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Reduce”.

Tempest Therapeutics Trading Down 3.9%

The firm’s fifty day simple moving average is $1.30 and its 200 day simple moving average is $1.91. The company has a market cap of $15.20 million, a price-to-earnings ratio of -0.16 and a beta of -1.73.

Tempest Therapeutics (NASDAQ:TPST) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($2.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($2.25). As a group, sell-side analysts expect that Tempest Therapeutics, Inc. will post -1.34 EPS for the current year.

Institutional Trading of Tempest Therapeutics

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in Tempest Therapeutics by 20.8% during the 3rd quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock worth $1,671,000 after acquiring an additional 27,952 shares during the period. Dimensional Fund Advisors LP acquired a new position in shares of Tempest Therapeutics during the fourth quarter worth about $33,000. Finally, Sabby Management LLC purchased a new position in Tempest Therapeutics during the fourth quarter worth about $513,000. Institutional investors and hedge funds own 22.52% of the company’s stock.

About Tempest Therapeutics

Tempest Therapeutics is a clinical?stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune?mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator?activated receptor alpha (PPAR?) and salt?inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first?in?class PPAR? antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.